PMID- 33469809
OWN - NLM
STAT- MEDLINE
DCOM- 20220216
LR  - 20220216
IS  - 1573-2568 (Electronic)
IS  - 0163-2116 (Linking)
VI  - 67
IP  - 1
DP  - 2022 Jan
TI  - Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, "Prediabetes," 
      Diabetes and Atherosclerosis.
PG  - 26-41
LID - 10.1007/s10620-021-06824-7 [doi]
AB  - Fat accumulation in the pancreas associated with obesity and the metabolic 
      syndrome (MetS) has been defined as "non-alcoholic fatty pancreas disease" 
      (NAFPD). The aim of this review is to describe the association of NAFPD with 
      obesity, MetS, type 2 diabetes mellitus (T2DM) and atherosclerosis and also 
      increase awareness regarding NAFPD. Various methods are used for the detection 
      and quantification of pancreatic fat accumulation that may play a significant 
      role in the differences that have been observed in the prevalence of NAFPD. 
      Endoscopic ultrasound provides detailed images of the pancreas and its use is 
      expected to increase in the future. Obesity and MetS have been recognized as 
      NAFPD risk factors. NAFPD is strongly associated with non-alcoholic fatty liver 
      disease (NAFLD) and it seems that the presence of both may be related with 
      aggravation of NAFLD. A role of NAFPD in the development of "prediabetes" and 
      T2DM has also been suggested by most human studies. Accumulation of fat in 
      pancreatic tissue possibly initiates a vicious cycle of beta-cell deterioration 
      and further pancreatic fat accumulation. Additionally, some evidence indicates a 
      correlation between NAFPD and atherosclerotic markers (e.g., carotid intima-media 
      thickness). Weight loss and bariatric surgery decreases pancreatic triglyceride 
      content but pharmacologic treatments for NAFPD have not been evaluated in 
      specifically designed studies. Hence, NAFPD is a marker of local fat accumulation 
      possibly associated with beta-cell function impairment, carbohydrate metabolism 
      disorders and atherosclerosis.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC part of Springer Nature.
FAU - Filippatos, T D
AU  - Filippatos TD
AD  - Metabolic Diseases Research Unit, Internal Medicine Laboratory, School of 
      Medicine, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion, 
      Crete, Greece. filtheo@uoc.gr.
FAU - Alexakis, K
AU  - Alexakis K
AD  - Metabolic Diseases Research Unit, Internal Medicine Laboratory, School of 
      Medicine, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion, 
      Crete, Greece.
FAU - Mavrikaki, V
AU  - Mavrikaki V
AD  - Metabolic Diseases Research Unit, Internal Medicine Laboratory, School of 
      Medicine, Faculty of Medicine, University of Crete, P.O. Box 2208, Heraklion, 
      Crete, Greece.
FAU - Mikhailidis, D P
AU  - Mikhailidis DP
AD  - Department of Clinical Biochemistry, Royal Free Campus, University College London 
      Medical School, University College London (UCL), London, NW3 2QG, UK.
AD  - Mohammed Bin Rashid University (MBRU) of Medicine and Health Sciences, Dubai, 
      United Arab Emirates.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210119
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
SB  - IM
MH  - Adiposity
MH  - Atherosclerosis/complications/diagnosis
MH  - Body Fat Distribution/*methods
MH  - Diabetes Mellitus, Type 2/complications/diagnosis
MH  - Humans
MH  - Metabolic Syndrome/complications/diagnosis
MH  - Obesity/complications/diagnosis
MH  - *Pancreas/diagnostic imaging/metabolism/pathology
MH  - *Pancreatic Diseases/complications/metabolism/pathology
MH  - Risk Factors
OTO - NOTNLM
OT  - Atherosclerosis
OT  - Metabolic syndrome
OT  - Non-alcoholic fatty liver disease
OT  - Non-alcoholic fatty pancreas disease
OT  - Obesity
OT  - Type 2 diabetes mellitus
EDAT- 2021/01/21 06:00
MHDA- 2022/02/17 06:00
CRDT- 2021/01/20 05:57
PHST- 2020/03/25 00:00 [received]
PHST- 2021/01/05 00:00 [accepted]
PHST- 2021/01/21 06:00 [pubmed]
PHST- 2022/02/17 06:00 [medline]
PHST- 2021/01/20 05:57 [entrez]
AID - 10.1007/s10620-021-06824-7 [pii]
AID - 10.1007/s10620-021-06824-7 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2022 Jan;67(1):26-41. doi: 10.1007/s10620-021-06824-7. Epub 2021 Jan 
      19.